newsfilter
← Latest News
GlobeNewswire·

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

ABEO
  • Abeona Therapeutics Inc. activated University of Florida Health (UF Health) in Gainesville, Florida, as its eighth Qualified Treatment Center (QTC) for administering ZEVASKYN (prademagene zamikeracel).
  • ZEVASKYN is the first & only autologous gene-modified cellular sheet therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
  • UF Health now serves as the sole treatment center for ZEVASKYN across the Southeastern United States.
  • The UF Health Epidermolysis Bullosa Clinic has already initiated patient identification & onboarding activities to support treatment access.
  • ZEVASKYN works by incorporating the functional COL7A1 gene into a patient's skin cells ex vivo to produce type VII collagen required for skin anchoring.
  • Serious safety risks include potential allergic reactions, anaphylaxis, cancer development requiring lifelong monitoring, & infection risks from human/animal materials used in production.
  • Patients can contact the UF Health EB Clinic at (352) 594-1500 or eb-clinic@ufl.edu for more information on receiving treatment.
  • Abeona Assist offers patient support services including insurance navigation, financial assistance, & logistical help via 1-855-223-6621 or www.abeonaassist.com.
  • Abeona Therapeutics maintains a fully integrated cGMP manufacturing facility in Cleveland, Ohio, for commercial production of ZEVASKYN.